NOVARTIS

Budget/Appropriations

Advanced Research Projects Agency for Health (ARPA-H) Biosimilars Drug Pricing Fiscal year 2023 Appropriations H.R. 6833 - Continuing Appropriations H.R.1, For the People Act of 2021 H.R.1319, American Rescue Plan Act of 2021 H.R.2471, Consolidated Appropriations Act for FY 2022 H.R.5376, Inflation Reduction Act Importation National Defense Authorization Act FY 2023 Prescription Drug User Fee Act (PDUFA) VII Value of Medicine

TargetedSENATE · HOUSE OF REPRESENTATIVES · Executive Office of the President (EOP) · White House Office

Copyright/Patent/Trademark

Antitrust Legislation Bayh-Dole Act Biopharmaceutical Intellectual Property Biosimilars BPCIA Compulsory licenses Data Exclusivity Intellectual Property Issues in Response to coronavirus Inter Parties Review at PTO Patent Litigation Reform and Issues Related to Post Grant Proceedings at PTO Patents S.1435, Affordable Prescriptions for Patients Act of 2021 S.225, Competition and Antitrust Law Enforcement Reform Act Section 101 H.R. 2883, the Stop Stalling Access to Affordable Medications H.R. 2891, the Preserve Access to Affordable Generics and Biosimilars Act H.R. 2873, the Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 2884, the Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act WTO TRIPS Waiver H.R. 5376 - Inflation Reduction Act